The first results of long-awaited PEACE-1 trial are in. They randomized newly diagnosed metastatic men to either prostate radiation or abiraterone or standard-of-care (SOC). SOC included docetaxel for many of the men.
Radiographic progression-free survival increased by 2.5 years (from 2.0 to 4.5 yrs) with addition of abiraterone to docetaxel. Time to castration resistance increased by 1.7 yrs (from 1.5 to 3.2 yrs).
The full results will tell us how much the prostate radiation adds, and the effect on overall survival. The analysis by metastatic burden will be important too.
Meanwhile, docetaxel+abiraterone+ADT should be considered the new standard of care.